Table 2. Neutralization of HIV pseudotype infectivity
% neutralization of§
mAb E2 epitope Half-maximal binding, μg/ml* Inhibition of E2-CD81 Reactivity with 293-T expressed HCV E1E2 HIV-H E1E2 HIV SF162
7/59 384-391 0.01 - NT <5 <5
6/82a 384-395 2.0 - NT <5 <5
6/16 384-395 0.02 - +/+ <5 <5
9/27 396-407 0.04 - +/+ ≥99 <5
9/86a cHVR 1.0 - NT <5 <5
3/11 412-423 0.02 + NT 70 <5
2/69a 432-443 NS + +/+ ≥99 <5
1/39 432-443 0.15 + NT 20 <5
7/16b 436-447 0.10 + +/+ ≥99 <5
11/20 436-447 0.02 + NT ≥99 <5
6/1a 464-471 1.20 - NT <5 <5
6/41a 480-493 NS + NT <5 <5
2/64a 524-531 0.08 + NT 40 <5
9/75 524-531 0.01 + +/+ <5 <5
6/53 544-551 0.80 - +/+ <5 <5
B4a1 HIV gp120 NA NA NA <5 ≥99
  • NA, not applicable; NT, not tested

  • * mAb recognition of truncated soluble E2, relative affinities are shown as the concentration (μg/ml) required to give half-maximal binding in a capture ELISA (8)

  • mAb (10 μg/ml) inhibition of soluble E2 binding to GST-humCD81 (8)

  • mAb (10 μg/ml) reactivity with nonpermeabilized and permeabilized 293-T cells transfected with NL4.3.Luc.R-E- and pE1E2 (depicted in Fig. 1) (represented as +/+ non-perm/perm cell recognition)

  • § mAb (10 μg/ml) neutralization of HIV-H E1E2 and HIV SF 162 (1 ng per well inoculum) infection of Huh-7.5 and Hos.CD4.R5 cells, respectively, as determined by inhibition of luciferase activity

  • cHVR, conformation-dependent epitope within the HVR